These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 27250788)

  • 21. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
    Wahi A; Manchanda N; Jain P; Jadhav HR
    Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bromodomains: A novel target for the anticancer therapy.
    Gokani S; Bhatt LK
    Eur J Pharmacol; 2021 Nov; 911():174523. PubMed ID: 34563497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
    Amemiya S; Yamaguchi T; Hashimoto Y; Noguchi-Yachide T
    Bioorg Med Chem; 2017 Jul; 25(14):3677-3684. PubMed ID: 28549889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
    Sartor GC; Powell SK; Brothers SP; Wahlestedt C
    J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
    Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
    Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.
    Sdelci S; Lardeau CH; Tallant C; Klepsch F; Klaiber B; Bennett J; Rathert P; Schuster M; Penz T; Fedorov O; Superti-Furga G; Bock C; Zuber J; Huber KV; Knapp S; Müller S; Kubicek S
    Nat Chem Biol; 2016 Jul; 12(7):504-10. PubMed ID: 27159579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small-molecule BET inhibitors in clinical and preclinical development and their therapeutic potential.
    Yu L; Wang Z; Zhang Z; Ren X; Lu X; Ding K
    Curr Top Med Chem; 2015; 15(8):776-94. PubMed ID: 25732788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromodomain inhibitors and therapeutic applications.
    Gajjela BK; Zhou MM
    Curr Opin Chem Biol; 2023 Aug; 75():102323. PubMed ID: 37207401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.
    Borck PC; Guo LW; Plutzky J
    Circ Res; 2020 Apr; 126(9):1190-1208. PubMed ID: 32324495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bromodomain biology and drug discovery.
    Zaware N; Zhou MM
    Nat Struct Mol Biol; 2019 Oct; 26(10):870-879. PubMed ID: 31582847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
    Olp MD; Zhu N; Smith BC
    Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A patent review of BRD4 inhibitors (2013-2019).
    Lu T; Lu W; Luo C
    Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
    [No Abstract]   [Full Text] [Related]  

  • 39. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
    Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
    J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.
    Wan L; Wen H; Li Y; Lyu J; Xi Y; Hoshii T; Joseph JK; Wang X; Loh YE; Erb MA; Souza AL; Bradner JE; Shen L; Li W; Li H; Allis CD; Armstrong SA; Shi X
    Nature; 2017 Mar; 543(7644):265-269. PubMed ID: 28241141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.